# HRS9531

Hengrui’s Oral GLP‑1/GIP Candidate Shows Promising 26‑Week Weight Loss in China — A Potential Game‑Changer for Obesity Care

Hengrui Medicine and Kailera Therapeutics reported positive top‑line results from a 166‑participant Phase II trial of ripubopetide, an oral GLP‑1/GIP dual agonist, showing up to 12.1% mean weight loss at 26 weeks and manageable vomiting rates. Hengrui will pursue Phase III studies in China while Kailera plans a global Phase II in 2026, though larger, longer trials are needed to confirm efficacy and safety.